Alteon Announces Investor Update Conference Call Wednesday, May 11, 2005, 4:00 p.m. Eastern time

Alteon Announces Investor Update Conference Call Wednesday, May
11, 2005, 4:00 p.m. Eastern time
--- Conference Call to be Webcast --- 


PARSIPPANY, N.J., May 5  /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT)
announced that it will hold a regularly scheduled investor update conference
call on Wednesday, May 11, 2005 at 4:00 p.m. ET.

Anyone interested in participating in the live conference call should RSVP to
Nancy Regan at .  There will be a full question and answer period during the
call.

The dial-in telephone number for the conference call will be 1-888-208-1812. 
International participants may call [phone]. Participants should call
approximately 5-10 minutes before 4:00 p.m.  In addition, the conference call
will be accessible through a webcast on the company website,
http://www.alteon.com/ in the Investor Relations section, and a digital
rebroadcast will be available through May 18, 2005 at 11:59 P.M. by dialing
1-888-203-1112, passcode 9407076 for domestic callers and [phone],
passcode 9407076 for international callers.

About Alteon

Alteon is developing several new classes of drugs that have shown the potential
to reverse or slow down diseases of aging and complications of diabetes.  These
compounds appear to have an impact on a fundamental pathological process caused
by the progressive formation of protein-glucose complexes called Advanced
Glycation End-products (A.G.E.s).  The formation and crosslinking of A.G.E.s
lead to a loss of flexibility and function in body tissues and organs and have
been shown to be a causative factor in many age- related diseases and diabetic
complications.  Alteon has created a library of novel classes of compounds
targeting the A.G.E. pathway.

Alteon's lead compound alagebrium chloride (formerly ALT-711), the only A.G.E.
Crosslink Breaker in advanced human testing, has shown promising results in
several Phase 2 trials and is being developed for systolic hypertension, heart
failure and erectile dysfunction.  Approximately 1,300 patients have been
involved in alagebrium's human clinical trials to date, of whom approximately
1,000 have received active compound.  Clinical studies of alagebrium include
the Phase 2b systolic hypertension trial, SPECTRA (Systolic Pressure Efficacy
and Safety Trial of Alagebrium), the Phase 2a heart failure study, PEDESTAL
(Patients with Impaired Ejection Fraction and Diastolic Dysfunction: Efficacy
and Safety Trial of ALagebrium), the Phase 2a EMERALD study (Evaluation of
Alagebrium in Erectile Dysfunction in Diabetic Males on PDE5 Inhibitors), as
well as a fourth study exploring mechanism of action in endothelial
dysfunction.

In February 2005, Alteon voluntarily and temporarily suspended enrollment of
new patients into the Company's ongoing alagebrium clinical studies pending
receipt of additional pre-clinical toxicity data.  In May 2005, the Company
announced encouraging interim results from these ongoing toxicity tests, and
announced its intention to conduct an interim analysis of the SPECTRA trial;
the results of both are expected approximately mid-year 2005.  The Company
expects that decisions regarding resumption of enrollment into each of the
trials will be made at that time.

For more detailed information about alagebrium, please visit the research and
development section of the Alteon website, http://www.alteon.com/.

Any statements contained in this press release that relate to future plans,
events or performance are forward-looking statements that involve risks and
uncertainties including, but not limited to, those relating to technology and
product development (including the possibility that early clinical trial
results may not be predictive of results that will be obtained in large-scale
testing or that any clinical trials will not demonstrate sufficient safety and
efficacy to obtain requisite approvals or will not result in marketable
products), regulatory approval processes, intellectual property rights and
litigation, competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange Commission. The
information contained in this press release is accurate as of the date
indicated.  Actual results, events or performance may differ materially. Alteon
undertakes no obligation to publicly release the result of any revision to
these forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. 

DATASOURCE: Alteon Inc.



CONTACT: Susan M. Pietropaolo, Director, Corporate Communications &

Investor Relations, [phone], fax, [phone]



Web site:  http://www.alteon.com/ 

Copyright